Men with prostate cancer will be the first group of patients in China to benefit from the recent clearance of Elekta’s (EKTA-B.ST) Clarity™ soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta’s premiere linear accelerator offering, Versa HD™, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.
Beijing China — Tuesday, November 4, 20142. GLOBOCAN 2012 (IARC) (http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
###
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com Twitter: @Elekta.
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242
Email: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Kris Walmsley, Corporate Communications Manager, Elekta ABTel: +46 70 537 9545
Email: kris.walmsley@elekta.comTime zone: CET: Central European Time